This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Hologic Gestione
Criteri Gestione verificati 4/4
Hologic Il CEO è Steve MacMillan, nominato in Dec2013, e ha un mandato di 12.33 anni. la retribuzione annua totale è $ 15.93M, composta da 7.9% di stipendio e 92.1% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.57% delle azioni della società, per un valore di $ 96.93M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.5 anni e 7.4 anni.
Informazioni chiave
Steve MacMillan
Amministratore delegato
US$15.9m
Compenso totale
| Percentuale dello stipendio del CEO | 7.88% |
| Mandato del CEO | 12.3yrs |
| Proprietà del CEO | 0.6% |
| Durata media del management | 2.5yrs |
| Durata media del Consiglio di amministrazione | 7.4yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Aggiornamento della narrazione • Apr 10
HOLX: Pending 79 Cash Buyout And Hold Stance Will Guide Near-Term Trading
Analysts now view Hologic’s value as effectively unchanged, with a refreshed price framework still centered around $76.67 per share as they factor in the pending $79 per share cash acquisition and recent downgrades to Hold related to the transaction’s expected early February close. Analyst Commentary Recent research focuses heavily on the pending all cash acquisition at up to $79 per share and how that affects the risk and reward for current shareholders.Aggiornamento della narrazione • Mar 26
HOLX: Pending 79 Cash Buyout And Hold Ratings Will Shape Near-Term Outcomes
Analysts now see Hologic's fair value edging to about $76.67 per share, with only minor tweaks to growth, margin and P/E inputs. They are also reflecting increased caution around the pending up to $79 per share cash acquisition by Blackstone and TPG, which has led to a shift in ratings to Hold.Aggiornamento della narrazione • Mar 12
HOLX: Pending 79 Cash Buyout And Hold Stance Will Guide Near-Term Outcomes
Analysts have kept their average price target for Hologic broadly unchanged at about $76.60, noting only minor tweaks to discount rate, revenue growth, profit margin, and future P/E assumptions as they factor in the pending $79 per share acquisition by Blackstone and TPG and recent rating changes to Hold. Analyst Commentary Recent research has shifted Hologic to more of a wait and see idea, as the pending buyout at up to $79 per share becomes the main anchor for valuation and expected outcomes.Aggiornamento della narrazione • Feb 26
HOLX: Pending 79 Cash Buyout And Hold Rating Will Define Event Path
Analysts have adjusted their price target on Hologic to $79.00 per share, reflecting updated assumptions regarding a future P/E multiple and the pending $79 per share acquisition by funds managed by Blackstone and TPG. Analyst Commentary Recent research updates have shifted toward a more neutral stance on Hologic, with the pending acquisition at $79 per share now the main reference point for valuation rather than long term growth assumptions.Aggiornamento della narrazione • Feb 11
HOLX: Buyout Terms And Neutral Ratings Will Shape Event-Driven Returns Through 2026
Analysts have trimmed their fair value estimate for Hologic to US$76.60 from about US$76.92, citing recent downgrades to Hold and Neutral, as the pending US$79 per share buyout by Blackstone and TPG narrows the expected upside. Analyst Commentary Recent research updates around Hologic largely reflect the pending all cash acquisition at US$79 per share, with several firms moving to more neutral stances as the share price tracks closer to the agreed takeout level.Aggiornamento della narrazione • Jan 26
HOLX: Buyout Terms And Neutral Ratings Will Frame Returns Through 2026
Narrative Update The analyst fair value estimate for Hologic has edged up by about $0.50 per share as analysts align their targets more closely with the pending private equity acquisition price of up to $79. They are also updating assumptions around the discount rate, modest revenue growth, and future P/E.Aggiornamento della narrazione • Jan 12
HOLX: Buyout Deal Terms And Rating Downgrades Will Guide Trading Through 2026
Our updated analyst price target for Hologic edges down slightly to about $76.42 per share. This reflects that analysts now anchor their views more tightly to the proposed Blackstone and TPG takeout value of up to $79 per share and the recent wave of rating downgrades to Neutral or Hold around that deal.Aggiornamento della narrazione • Dec 18
HOLX: Buyout Terms And Neutral Ratings Will Shape Trading Through 2026
We trim our Hologic price target slightly to approximately $76.50, as analysts coalesce around the proposed Blackstone and TPG takeout valuation of up to $79.00 per share and see limited upside beyond the agreed acquisition terms. Analyst Commentary Street research following the announced takeout has converged around the proposed valuation, with most firms adjusting ratings and targets to reflect a view that the deal price largely caps near term upside.Aggiornamento della narrazione • Dec 04
HOLX: Buyout Deal And Neutral Ratings Will Define Shares Through 2026
The analyst price target for Hologic has inched higher by approximately $0.33 to $76.50, as analysts factor in slightly stronger long term growth and margin assumptions while anchoring valuation to the proposed Blackstone and TPG takeout price near $79 per share. Analyst Commentary Analyst reaction to the proposed Blackstone and TPG acquisition has been mixed, with most firms converging around price targets in the mid to high $70s and resetting ratings to more neutral stances as upside becomes more constrained by the agreed takeout price.Aggiornamento della narrazione • Nov 20
HOLX: Acquisition Agreement With Blackstone and TPG Will Shape Stock Outlook Through 2026
Hologic’s analyst price target has increased modestly from $75.08 to $76.17 per share. Analysts view the proposed $79 per share acquisition by Blackstone and TPG as providing a fair valuation and setting a near-term ceiling for the stock.Aggiornamento della narrazione • Nov 05
HOLX: Downgrades And Buyout Agreement Will Shift Near-Term Share Performance
Analysts have modestly increased their price target for Hologic from approximately $73.54 to $75.08. They cite the recently announced acquisition by Blackstone and TPG as supportive of current valuation levels, given the company's operating challenges and outlook.Aggiornamento della narrazione • Oct 22
Analysts Raise Hologic Targets Amid Strong Results and Positive Acquisition Momentum
Hologic's analyst price target has increased by $1.11, as analysts cite improving financial performance and the impact of the recent acquisition agreement as key factors that support the higher valuation. Analyst Commentary Bullish Takeaways Bullish analysts increased their price targets, pointing to Hologic's improved financial results and raised full-year guidance amid strong recent revenue and EPS performance.Aggiornamento della narrazione • Sep 28
Preventive Healthcare And Advanced Diagnostics Will Shape Future Markets
Despite strong quarterly outperformance, higher 2025 guidance, and increased buyout speculation, Hologic's consensus analyst price target was modestly reduced from $73.87 to $72.43 as fiscal 2025 estimates were recalibrated to reflect current demand trends and tariff expectations. Analyst Commentary Strong revenue and EPS outperformance in the recent quarter, with management raising full-year 2025 guidance.Articolo di analisi • Sep 13
Returns At Hologic (NASDAQ:HOLX) Appear To Be Weighed Down
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Aggiornamento della narrazione • Sep 05
Preventive Healthcare And Advanced Diagnostics Will Shape Future Markets
Despite strong Q3 results, raised FY25 guidance, and increased investor interest from buyout speculation, Hologic’s consensus price target remains unchanged at $73.87 as estimates are now better aligned with actual demand and tariff risks. Analyst Commentary Raised FY25 guidance and Q3 results substantially beat revenue and EPS expectations, demonstrating robust operational performance.Articolo di analisi • Aug 04
Analysts Have Made A Financial Statement On Hologic, Inc.'s (NASDAQ:HOLX) Third-Quarter Report
Investors in Hologic, Inc. ( NASDAQ:HOLX ) had a good week, as its shares rose 2.2% to close at US$67.16 following the...Articolo di analisi • Jul 19
Is Hologic, Inc. (NASDAQ:HOLX) Trading At A 38% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Hologic fair value estimate is US$103 Hologic is estimated to...Articolo di analisi • Jul 01
The Price Is Right For Hologic, Inc. (NASDAQ:HOLX)
With a price-to-earnings (or "P/E") ratio of 26.1x Hologic, Inc. ( NASDAQ:HOLX ) may be sending bearish signals at the...Articolo di analisi • Jun 13
Is Hologic (NASDAQ:HOLX) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • May 06
Hologic: Soft Performance, But Cheap Enough
Summary Hologic, Inc.'s appeal has increased due to reduced debt, serial buybacks, and modest valuations, despite recent negative organic growth and pricey acquisitions. The company has shown solid long-term growth, reducing leverage significantly and buying back shares, but recent performance has been soft with flattish sales and earnings. Despite a slight cut in earnings guidance and soft organic growth, Hologic's shares now trade at attractive multiples with very manageable leverage. While cautious due to recent underperformance and expensive acquisitions, I remain upbeat on HOLX stock and plan to add to my long position. Read the full article on Seeking AlphaSeeking Alpha • Jan 17
Hologic: Reasonably, But Not Compellingly Valued
Summary Hologic, Inc. is down approximately 20% from recent highs despite strong quarterly results. The company continues to grow organically and via a series of 'bolt-on' acquisitions. Management also recently added significantly to the company's stock buyback authorization. An updated analysis around Hologic, Inc. follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Oct 28
Hologic: Continued Room Amidst Bolt-On M&A Efforts
Summary Hologic, Inc.'s focus on women's health and strategic M&A, despite pandemic headwinds, positions it for continued growth with a projected $4 billion revenue in 2024. Trading at 20 times earnings, Hologic's quality and growth potential justify its valuation, with shares having risen 10% since May. The company maintains solid organic growth, reducing net debt and executing strategic acquisitions like Endomagnetics and Gynesonics, enhancing its market position. With pandemic-related diagnostics sales declining, Hologic's consistent earnings and strategic moves make it a compelling investment, despite shares not being cheap. Read the full article on Seeking AlphaSeeking Alpha • Aug 27
Hologic Has A Lot Of Fine Qualities, But A Discount Valuation Isn't Among Them
Summary Hologic has been outperforming peers but underperforming the broader medical device sector, with shares up about 5% since my last analysis. Fiscal Q3 results showed consistent beats in Diagnostics, Breast Health, and Surgical segments, but Skeletal Health faced setbacks due to supplier issues. Management has continued to optimize the pandemic-driven surge in Panther placements, with the BV CV/TV panel growing to the second-largest panel in the company's portfolio. Hologic has been a share gainer in molecular diagnostics and is active in M&A, but long-term 5% to 7% revenue growth targets may be too challenging. Long-term revenue growth around 5%, near-term EBITDA margins in the low-30%s, and long-term FCF growth of around 6% support today's valuation and single-digit returns, but Hologic doesn't stand out as undervalued. Read the full article on Seeking AlphaAnalisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Dec 27 2025 | n/a | n/a | US$544m |
| Sep 27 2025 | US$16m | US$1m | US$566m |
| Jun 28 2025 | n/a | n/a | US$557m |
| Mar 29 2025 | n/a | n/a | US$557m |
| Dec 28 2024 | n/a | n/a | US$744m |
| Sep 28 2024 | US$16m | US$1m | US$790m |
| Jun 29 2024 | n/a | n/a | US$702m |
| Mar 30 2024 | n/a | n/a | US$467m |
| Dec 30 2023 | n/a | n/a | US$515m |
| Sep 30 2023 | US$16m | US$1m | US$456m |
| Jul 01 2023 | n/a | n/a | US$484m |
| Apr 01 2023 | n/a | n/a | US$753m |
| Dec 31 2022 | n/a | n/a | US$990m |
| Sep 24 2022 | US$14m | US$1m | US$1b |
| Jun 25 2022 | n/a | n/a | US$2b |
| Mar 26 2022 | n/a | n/a | US$2b |
| Dec 25 2021 | n/a | n/a | US$2b |
| Sep 25 2021 | US$15m | US$1m | US$2b |
| Jun 26 2021 | n/a | n/a | US$2b |
| Mar 27 2021 | n/a | n/a | US$2b |
| Dec 26 2020 | n/a | n/a | US$1b |
| Sep 26 2020 | US$14m | US$1m | US$1b |
| Jun 27 2020 | n/a | n/a | US$497m |
| Mar 28 2020 | n/a | n/a | US$453m |
| Dec 28 2019 | n/a | n/a | US$84m |
| Sep 28 2019 | US$12m | US$1m | -US$204m |
Compensazione vs Mercato: La retribuzione totale di Steve ($USD 15.93M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 14.79M ).
Compensazione vs guadagni: La retribuzione di Steve è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Steve MacMillan (61 yo)
12.3yrs
Mandato
US$15,931,655
Compensazione
Mr. Stephen P. MacMillan, also known as Steve, serves as a Director of EZ LIFT Rescue Systems, Inc. and Business Leaders for Michigan. He served as an Independent Chairman of the Board at Illumina, Inc. fr...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Chairman | 12.3yrs | US$15.93m | 0.57% $ 96.9m | |
| Chief Financial Officer | 7.7yrs | US$4.39m | 0.025% $ 4.3m | |
| Chief Operating Officer | 2.3yrs | US$5.08m | 0.0091% $ 1.5m | |
| Group President of International | no data | US$3.46m | 0.050% $ 8.4m | |
| President of Diagnostic Solutions | 3yrs | US$3.13m | 0.0026% $ 440.8k | |
| Chief Information Officer | 4.8yrs | Nessun dato | Nessun dato | |
| Corporate Vice President of Investor Relations | 1.3yrs | Nessun dato | Nessun dato | |
| General Counsel | less than a year | Nessun dato | 0.013% $ 2.1m | |
| Senior Vice President of Global Human Resources | 1.7yrs | Nessun dato | 0.0034% $ 575.9k | |
| VP & Chief of Staff | 12.3yrs | Nessun dato | Nessun dato | |
| Senior Vice President of Global Supply Chain & Regulatory Affairs | 2.5yrs | Nessun dato | Nessun dato | |
| President of GYN Surgical Solutions | 2.3yrs | Nessun dato | 0.0078% $ 1.3m |
2.5yrs
Durata media
55yo
Età media
Gestione esperta: Il team dirigenziale di HOLX è considerato esperto (durata media dell'incarico 2.5 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Chairman | 12.3yrs | US$15.93m | 0.57% $ 96.9m | |
| Independent Director | 1.3yrs | US$355.90k | 0.0034% $ 579.3k | |
| Independent Director | 3.3yrs | US$329.97k | 0.00078% $ 131.7k | |
| Independent Director | 7.4yrs | US$329.97k | 0.0042% $ 700.9k | |
| Independent Director | 8.9yrs | US$354.97k | 0.0084% $ 1.4m | |
| Independent Director | 1yr | US$258.46k | 0.00078% $ 131.7k | |
| Independent Director | 14.4yrs | US$329.97k | 0.021% $ 3.6m | |
| Lead Independent Director | 9.3yrs | US$384.97k | 0.0093% $ 1.6m | |
| Independent Director | 2.6yrs | US$344.97k | 0.0019% $ 315.8k |
7.4yrs
Durata media
61yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di HOLX sono considerati esperti (durata media dell'incarico 7.4 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/04/06 09:03 |
| Prezzo dell'azione a fine giornata | 2026/04/06 00:00 |
| Utili | 2025/12/27 |
| Utili annuali | 2025/09/27 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Hologic, Inc. è coperta da 25 analisti. 15 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| David Toung | Argus Research Company |
| Charles Butler | Barclays |
| Charley Jones | Barrington Research Associates, Inc. |